Navigation Links
ATS Medical Announces Participation in the Annual Meeting of the American Association for Thoracic Surgeons
Date:5/7/2009

MINNEAPOLIS, May 7 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced participation in the upcoming 89th Annual Meeting of the American Association for Thoracic Surgeons (AATS) being held in Boston from May 10-13, 2009. The Annual AATS meeting is key gathering of cardiovascular surgeons, nurses and allied health professionals from around the world that provides an excellent venue for the Company to exhibit its growing portfolio of clinically relevant products designed to meet the needs of cardiac surgeons and their patients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)

Highlighting ATS's broad product offering is the ATS 3f(R) Aortic Bioprosthesis designed to replace the patient's diseased valve. The ATS 3f Aortic Bioprosthesis is a revolutionary next generation stentless pericardial aortic tissue valve that is unlike any other valve with its tubular design that restores continuity between the annulus and the sinotubular junction. By restoring this continuity, the ATS 3f Aortic Bioprosthesis is the only aortic valve that preserves the sinuses and restores native valve stress distribution and physiologic blood flow. This valve design provides surgeons and patients with a potentially more durable solution to aortic valve replacement. In addition, ATS is sponsoring a symposium on Sunday, May 10th at 7:00 pm at the Skywalk Observatory in the Prudential Tower entitled, "The ATS 3f Revolution," which will be hosted by several preeminent cardiac surgeons including Richard Shemin, MD, from UCLA, Los Angeles, Allan Stewart, MD, from Columbia University Medical Center, New York, and Sven Martens, MD, from JW Goethe University, Frankfurt.

In the field of ablation technology the Company will be exhibiting its ATS CryoMaze(R) Surgical Ablation System used to treat patients with cardiac arrhythmias. The ATS CryoMaze(R) Surgical System provides results similar to the gold standard cut-and-sew Cox Maze III procedure and is being used by a growing number of surgeons as their ablation technology of choice. It will be the topic of in-booth presentations by W. Randolph Chitwood, Jr., MD, of East Carolina University and Edward Raines, MD, JD, from Bryan LGH Medical Center, Lincoln, Nebraska.

The mechanical heart valve segment will feature the flagship ATS Open Pivot(R) Heart Valve and its newest advancement, the ATS Open Pivot(R) AP360(TM) with enhanced surgical implant characteristics. The family of ATS mechanical heart valves features a unique open pivot design that results in exceptional hemodynamic performance and a low risk profile. Stephen Westaby, BSc, MS, PhD, from John Radcliffe Hospital, Oxford will present at the booth his "15-year, Single Surgeon Experience with the ATS Open Pivot Mechanical Valve".

The ATS Simulus(R) Annuloplasty product line, designed for the heart valve repair market, will be showcased with special focus on the new ATS Simulus Semi-Rigid Annuloplasty Ring. Paul Davis, MD, of St. Francis Hospital, Wilmington, Delaware will present his experience with this ring during his in-booth presentation entitled "Physiological Correction with the ATS Simulus Semi Rigid Ring".

Hands-on demonstrations of all the unique technologies from ATS Medical will be available at the ATS Medical booth #603.

About ATS Medical

ATS Medical, Inc. is dedicated to "Advancing The Standards" of cardiac surgery through the development, manufacturing and marketing of innovative products and services for the treatment of structural heart disease. ATS Medical serves the cardiac surgery community by focusing on two distinct but operationally synergistic market segments: heart valve disease therapy and surgical ablation of cardiac arrhythmias.

ATS was originally founded to develop the ATS Open Pivot(R) Heart Valve as a new mechanical heart valve standard of care. Today the Open Pivot heart valve is the preferred mechanical heart valve in many markets around the world and the fastest growing mechanical prosthesis in the market. Building on this legacy and addressing the largest market segment in heart valve therapy, the ATS 3f(R) brand encompasses an innovative tissue heart valve portfolio to address conventional open surgery requirements as well as the growing demand for less invasive sutureless based procedures. The ATS 3f(R) portfolio includes offerings at various stages including early product development, pivotal clinical trials, and market commercialization. Completing the portfolio in heart valve therapy is the ATS Simulus(R) annuloplasty product line. Simulus products assist the surgeon in repairing a patient's native heart valve as an alternative to replacement. Continuing ATS Medical's focus on serving the cardiac surgery community are the ATS CryoMaze(TM) products for surgical cryoablation of cardiac arrhythmias. ATS CryoMaze(TM) products are used by surgeons to treat patients suffering from cardiac arrhythmias, the largest and fastest growing form of structural heart disease in populations over 60 years of age. The ATS Medical web site is http://www.atsmedical.com.

Safe Harbor

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2008 and its most recent quarterly report on Form 10-Q.


'/>"/>
SOURCE ATS Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. BioMS Medical announces its intention to renew a normal course issuer bid
6. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Globus Medical Announces Record 2nd Quarter 2007 Results
10. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
11. China Medical Technologies Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Yorba Linda, Ca (PRWEB) , ... January 18, ... ... interactive virtual events for tech innovators, engineers, and scientists from around the world, ... Corporate American News. The awards program is based entirely on merit and decided ...
(Date:1/19/2017)... 2017 The global biotechnology services outsourcing ... by 2025, according to a new report by ... adaptive of the function of outsourcing certain clinical ... the services outsourced, clinical trial management and contract ... Johnson was the first pharmaceutical company to outsource ...
(Date:1/19/2017)... 2017 BD (Becton, Dickinson and Company) (NYSE: ... will host a live webcast of its Annual Meeting of Shareholders ... The webcast can be accessed from the BD corporate website ... January 31, 2017. ... About BD BD is a global medical technology company ...
(Date:1/18/2017)... Jan. 18, 2017   Boston Biomedical , an ... to target cancer stemness pathways, will feature data from ... at the 2017 ASCO Gastrointestinal Cancers Symposium, held from ... Napabucasin is an orally-administered investigational agent ... i Cancer stem cells (CSCs) possess the property ...
Breaking Biology Technology:
(Date:12/16/2016)... global wearable medical device market, in terms of value, is projected ... in 2016, at a CAGR of 18.0% during the forecast period. ... Growth in ... launch of a growing number of smartphone-based healthcare apps compatible with ... increasing focus on physical fitness. Furthermore, growing trend ...
(Date:12/15/2016)...  There is much more to innovative access systems ... Continental will demonstrate the intelligence of today,s solutions at ... Through the combination of the keyless entry and start ... the international technology company is opening up new possibilities ... "The integration of biometric elements brings our expertise ...
(Date:12/7/2016)... According to a new market research report "Emotion Detection ... Voice Recognition), Service, Application Area, End User, And Region - Global Forecast to ... 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a Compound ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):